SkinCare Physicians

New Cosentyx® treatment can clear skin of patients with psoriasis

Published on Jun 4th, 2015 by Jeffrey Sobell

While there is no cure for psoriasis, an autoimmune skin disease, the science of psoriasis therapies is evolving at a very rapid pace. The recent Cosentyx® approval heralds a new era for psoriasis treatment at SkinCare Physicians’ Psoriasis Treatment Center near Boston.

Cosentyx® (secukinumab), a biologic therapy developed specifically for psoriasis, is now available for adults suffering from moderate-to-severe psoriasis. This is the first of several highly anticipated “second generation” biologics to complete rigorous testing and become available to treat this significant life-impacting disease.

Cosentyx® targets interleukin-17 (IL-17), one of the key chemical hormones that are elevated in people who have psoriasis. We now know that psoriasis is driven by underlying and excessive inflammation, and IL-17 is one of the critical entities involved in this process.

With this novel treatment, clear skin may now be a reality for patients suffering from psoriasis. In clinical trials, the success rate was astounding with over 70% of subjects achieving clearance or almost clearance of their psoriasis within 16 weeks.  Common side effects included uncomplicated cold symptoms, headache and mild diarrhea.

Before and after photos of psoriasis treatment Cosentyx

PASI 90 means that patients experienced a 90% or more reduction in their Psoriasis Area and Severity Index (PASI)
Picture courtesy of Novartis Pharmaceuticals Corporation

Cosentyx® joins Enbrel®, Humira®, Stelara® and Remicade ® as biologic options for treating moderate-to-severe psoriasis.  The addition of Cosentyx® to our psoriasis treatment armamentarium is a big win for patients still suffering from this disease. The odds are now exceedingly high that any patient who medically is a candidate for these therapies will find a treatment that works for them.

And the good news is that this is just the beginning.  There are at least 4 other promising second generation biologic agents for psoriasis currently in their final stages of testing that may see approval in the next 1-3 years.  It is an evolving and exciting time, and our Psoriasis Treatment Center in Boston has never been more equipped to help patients manage this disease.

Learn more about psoriasis:

Find Dr. Jeffrey Sobell on Google+

2 Responses to New Cosentyx® treatment can clear skin of patients with psoriasis

Leave a Reply

Fields marked with * are required.

Back to top

Our Promise

Our team of renowned physicians and experienced support staff is committed to excellence in medical skin care and cosmetic procedures with a patient-centered focus for women and men in the greater Boston area and beyond.

Request a Consultation

So Long Double Chin, No Surgery Necessary

Introducing KYBELLA™, the only treatment proven to reduce a double chin with safe, simple injections.

Learn More

Contact Us

The form below should not be used by patients to communicate clinical questions to SkinCare Physicians. It is not a patient portal. If your message is of an urgent, clinical or confidential nature, please call us instead at 1-617-383-8201.


 Please email me news and special offers

 termsAccepted

captcha

Chestnut Hill, MA (617) 731-1600

SkinCare Physicians®
1244 Boylston Street (Route 9)
Chestnut Hill, Massachusetts 02467

Phone: (617) 731-1600 Fax: (617) 731-1601

Medical Website Design & Marketing
by Etna Interactive

SkinCare Physicians®
1244 Boylston Street (Route 9)
Chestnut Hill, Massachusetts 02467

Phone: (617) 731-1600 Fax: (617) 731-1601

Medical Website Design & Marketing by Etna Interactive

The dermatologists and other medical professionals at SkinCare Physicians specialize in a wide range of dermatology treatments and services, including laser hair removal, laser skin treatment, hair transplant, eyelid surgery, body contouring, psoriasis, skin cancer, BOTOX® Cosmetic, fillers, and Thermage®. From their offices in Chestnut Hill, they serve Boston, Brookline, Cambridge, Newton and Wellesley.